Acasti Pharma Inc (ACST.V)

Name: Acasti Pharma Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-09-30

Latest Quarter

2025-09-30

Revenue

$0.0

Net Income

-$938K

Operating Margin

N/A

Free Cash Flow

-$14.9M

Debt / Assets

7.5%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Acasti Pharma Inc (ACST.V).
Income Statement (Quarterly)	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Revenue	0	0	0	0
Cost of Revenue	0	0	2,000	0
Gross Profit	0	0	-2,000	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	1,961,000	2,133,000	1,547,000	1,509,000
Operating Expenses	2,529,000	3,090,000	3,181,000	3,704,000
Operating Income	-2,529,000	-3,090,000	-3,183,000	-3,704,000
Interest Expense	0	0	0	0
Income Before Tax	-938,000	-3,362,000	-382,000	-4,760,000
Income Tax Expense	0	0	-1,018,000	-605,000
Net Income	-938,000	-3,362,000	636,000	-4,155,000
Per Share
EPS	-0.06	-0.21	0.05	-0.36
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Acasti Pharma Inc (ACST.V).
Income Statement (Annual)	2025-03-31	2024-03-31	2022-12-31
Revenue	0	0	14,249,000
Cost of Revenue	0	11,000	67,215,000
Gross Profit	0	-11,000	-52,966,000
Operating Expenses
R&D Expenses	0	0	0
SG&A Expenses	7,161,000	6,673,000	20,189,000
Operating Expenses	16,679,000	11,301,000	12,665,000
Operating Income	-16,679,000	-11,312,000	-73,155,000
Interest Expense	0	0	0
Income Before Tax	-12,767,000	-14,630,000	-64,685,000
Income Tax Expense	-3,199,000	-1,777,000	230,000
Net Income	-9,568,000	-12,853,000	-64,915,000
Per Share
EPS	-0.79	-1.73	-0.99
EPS Diluted	0.00	0.00	0.00

Balance sheet quarterly history for Acasti Pharma Inc (ACST.V).
Balance Sheet (Quarterly)	2025-03-31	2024-03-31	2022-12-31
Assets
Cash and Cash Equivalents	22,133,000	23,005,000	112,488,000
Short Term Investments	0	0	0
Net Receivables	126,000	722,000	6,533,000
Inventory	0	0	1
Total Current Assets	22,712,000	24,010,000	147,196,000
Property Plant Equipment	15,000	24,000	21,976,000
Goodwill and Intangibles	49,266,000	49,266,000	0
Total Assets	71,993,000	73,300,000	170,454,000
Liabilities
Account Payables	601,000	1,007,000	5,488,000
Short Term Debt	0	0	0
Total Current Liabilities	1,930,000	1,684,000	35,632,000
Long Term Debt	0	0	911,000
Total Liabilities	5,383,000	11,557,000	67,937,000
Shareholders Equity
Retained Earnings	-220,687,000	-211,119,000	-287,681,000
Total Shareholders Equity	66,610,000	61,743,000	102,517,000

Balance sheet annual history for Acasti Pharma Inc (ACST.V).
Balance Sheet (Annual)	2025-03-31	2024-03-31	2022-12-31
Assets
Cash and Cash Equivalents	22,133,000	23,005,000	112,488,000
Short Term Investments	0	0	0
Net Receivables	126,000	722,000	6,533,000
Inventory	0	0	1
Total Current Assets	22,712,000	24,010,000	147,196,000
Property Plant Equipment	15,000	24,000	21,976,000
Goodwill and Intangibles	49,266,000	49,266,000	0
Total Assets	71,993,000	73,300,000	170,454,000
Liabilities
Account Payables	601,000	1,007,000	5,488,000
Short Term Debt	0	0	0
Total Current Liabilities	1,930,000	1,684,000	35,632,000
Long Term Debt	0	0	911,000
Total Liabilities	5,383,000	11,557,000	67,937,000
Shareholders Equity
Retained Earnings	-220,687,000	-211,119,000	-287,681,000
Total Shareholders Equity	66,610,000	61,743,000	102,517,000

Cash flow quarterly history for Acasti Pharma Inc (ACST.V).
Cash Flow Statement (Quarterly)	2025-03-31	2024-03-31	2022-12-31
Operating Activities
Net Income	-9,568,000	-12,853,000	-64,915,000
Depreciation & Amortization	7,000	11,000	3,602,000
Stock Based Compensation	730,000	913,000	5,043,000
Change in Working Capital	342,000	-1,280,000	-341,000
Operating Cash Flow	-14,904,000	-12,333,000	-19,997,000
Investing Activities
Capital Expenditure	0	-22,000	-5,017,000
Investments	0	-22,000	-5,017,000
Investing Cash Flow	0	104,000	-5,017,000
Financing Activities
Debt Repayment	0	0	-2,850,000
Common Stock Issued/Repurchased	14,999,000	7,338,000	0
Dividends Paid	0	0	0
Financing Cash Flow	14,032,000	7,359,000	72,271,000
Summary
Free Cash Flow	-14,904,000	-12,355,000	-25,014,000
Net Change in Cash	-872,000	-4,870,000	46,532,000

Cash flow annual history for Acasti Pharma Inc (ACST.V).
Cash Flow Statement (Annual)	2025-03-31	2024-03-31	2022-12-31
Operating Activities
Net Income	-9,568,000	-12,853,000	-64,915,000
Depreciation & Amortization	7,000	11,000	3,602,000
Stock Based Compensation	730,000	913,000	5,043,000
Change in Working Capital	342,000	-1,280,000	-341,000
Operating Cash Flow	-14,904,000	-12,333,000	-19,997,000
Investing Activities
Capital Expenditure	0	-22,000	-5,017,000
Investments	0	-22,000	-5,017,000
Investing Cash Flow	0	104,000	-5,017,000
Financing Activities
Debt Repayment	0	0	-2,850,000
Common Stock Issued/Repurchased	14,999,000	7,338,000	0
Dividends Paid	0	0	0
Financing Cash Flow	14,032,000	7,359,000	72,271,000
Summary
Free Cash Flow	-14,904,000	-12,355,000	-25,014,000
Net Change in Cash	-872,000	-4,870,000	46,532,000